EmetAbba is a one-dose gene replacement therapy for nonketotic hyperglycinemia. It uses an AAV vector to deliver a working copy of the gene that's broken in NKH, with the goal of letting cells clear glycine the way they're supposed to. The family has called it potentially curative, and it will be tested for the first time in people in Drake and Vivian's trial.
The name is deeply personal. Tarah and Eric O'Sullivan wanted the drug to bear God's name. "Emet" is a Hebrew word for truth and faithfulness, and "Abba" means father, so the family translates it as "Faithful Father." You'll also see it written as Emetabba or #Emetabba.
EmetAbba is the fruit of years of work. The Drake Rayden Foundation began funding gene therapy research in 2019, and the family says they partnered with researchers around the world before finding the right combination. Manufacturing contracts were signed in December 2025.
Tarah has said: "I believe this treatment is going to rewrite the future for NonKetotic Hyperglycinemia.....because we trust the ONE who holds the pen." The trial is planned for late 2026. Help close the final funding gap.
Sources: Saving Drake and Vivian (GoFundMe updates) · U.S. FDA: What is Gene Therapy?
Give
Cover an inch of the trial
Every $1,000 covers one inch of the trial. $252,210 to go.
Share
Share this answer
One post can reach the person who covers the rest. It costs nothing and takes ten seconds.
More ways to share